Profound Medical Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Profound Medical Corp. on January 6, 2026. The filing serves as a Regulation FD disclosure regarding a significant commercial milestone for the Company's TULSA-PRO® system.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific operational event and does not contain financial statements or quantitative financial data.
Material Changes and Operational Milestones
- First Non-Clinical-Trial Treatment: The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the Company's TULSA-PRO® system.
- Significance: This event marks a transition from clinical trial usage to commercial or standard-of-care application at a major academic medical center.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard legal disclaimers. The press release associated with this item is furnished as Exhibit 99.1 and is explicitly stated not to be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the patient treatment and future commercialization plans.
- Confirm whether this milestone triggers any specific revenue recognition or partnership agreements not detailed in this 8-K.
- Monitor subsequent filings for financial impact resulting from the adoption of the TULSA-PRO® system at The Johns Hopkins Hospital.